Takeda-backed Ascentage Pharma prices $126M U.S. IPO

Ascentage Pharma Group (AAPG) (AAPGV) (OTCPK:ASPHF), which is backed by Takeda (NYSE:TAK), has priced a $126M U.S. initial public offering.

The China-based drug developer priced 7.33M shares at $17.25 per share, which is expected to raise around $126M. Underwriters were granted a 30-day option